The release of ICH E6(R3) in January 2025 marks the most significant evolution in Good Clinical Practice (GCP) guidelines in over a decade. More than a revision, E6(R3) marks a shift from traditional practices—making participant safety and data reliability not just priorities, but design drivers, and introducing risk-based proportionality as a foundational approach.
The release of ICH E6(R3) in January 2025 marks the most significant evolution in Good Clinical Practice (GCP) guidelines in over a decade. More than a revision, E6(R3) marks a shift from traditional practices—making participant safety and data reliability not just priorities, but design drivers, and introducing risk-based proportionality as a foundational approach.
Clinical research drives medical progress. Advarra ensures participant safety and ethical standards through expert IRB oversight for life-changing therapies.
Clinical research drives medical progress. Advarra ensures participant safety and ethical standards through expert IRB oversight for life-changing therapies.
Launched in January 2025, the Association of Multisite Research Corporations (AMRC) was set up by its founding members to advance
Our webinar discusses key near-term trends and regulations and investigate persistent challenges frequently throwing even the most efficient teams off track. Advarra and industry representatives will dive deeper into achieving critical milestones across study startup, conduct, and close out that every project manager should optimize.
Fostering Knowledge Exchange Across the Cancer Research Community Timely discussions. Expert perspectives. Illuminating the path to progress. Fostering Knowledge Exchange
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Advarra Single Sign-On (SSO) for user authentication allows users to access all SSO-enabled Advarra products in one place using just one set of credentials.
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
Learn about the challenges sites face and see how sponsors and CROs can work more collaboratively with sites to improve study startup and address the changing clinical trial landscape.
